Yasutoshi Kuboki

Sep 9, 2024 | digitalcommons.library.tmc.edu | Yasutoshi Kuboki |Marwan Fakih |John Strickler |Rona Yaeger

The current third-line (and beyond) treatment options for RAS-mutant metastatic colorectal cancer have yielded limited efficacy. At the time of study start, the combination of sotorasib, a KRAS (Kirsten rat sarcoma viral oncogene homolog)-G12C inhibitor, and panitumumab, an epidermal growth factor receptor (EGFR) inhibitor, was hypothesized to overcome treatment-induced resistance.